INOVIO’s COVID-19 vaccine candidate provided broad cross-reactive immune responses In humans against variants
On Apr. 15, 2021, Inovio Pharmaceuticals announced the results of a study focusing on the human immune responses induced by INOVIO’s DNA vaccine candidate for COVID-19, INO-4800, against variants of concern.
The results showed that INO-4800 induced a robust T cell response against all spike protein variants tested, which the company believes will be key in providing protection against SARS-CoV-2 variants, in addition to providing similar levels of neutralizing activity against both the UK and Brazilian variants as those against the original strain.
Tags:
Source: Inovio Pharmaceuticals
Credit: Photo: Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility, Fort Detrick, Maryland. Credit: National Institute of Allergy and Infectious Diseases.
